Anxiety, Stress
Conditions
Brief summary
A randomized, blinded, placebo-controlled, direct-to-consumer study assessing the impact of health and wellness products on feelings of anxiety, stress and other health outcomes
Detailed description
This is a randomized, blinded, placebo-controlled study conducted with up to 300 adult participants per study arm, age 21 and older and residing in the United States. Eligible participants will (1) endorse a desire for less feelings of anxiety and/or stress, (2) indicate an interest in taking a health and wellness product to potentially improve their anxiety and/or stress, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants with known liver or kidney disease, heavy drinkers, and those who are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded. Self-reported data will be collected electronically from eligible participants over 5 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Interventions
DIETARY_SUPPLEMENTRadicle Calm Study Active Product 2.1
Participants will use their Radicle Calm Active Product 2.1 as directed for a period of 4 weeks.
DIETARY_SUPPLEMENTRadicle Calm Study Placebo Control 1
Participants will use their Radicle Calm Placebo Control Product 1 as directed for a period of 4 weeks.
DIETARY_SUPPLEMENTRadicle Calm Study Placebo Control 2
Participants will use their Radicle Calm Placebo Control Product 2 as directed for a period of 4 weeks.
DIETARY_SUPPLEMENTRadicle Calm Study Active Product 1.1
Participants will use their Radicle Calm Active Product 1.1 as directed for a period of 4 weeks.
DIETARY_SUPPLEMENTRadicle Calm Study Active Product 2.2
Participants will use their Radicle Calm Active Product 2.2 as directed for a period of 4 weeks.
Sponsors
Radicle Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.
Intervention model description
Participants will be stratified based on gender at birth then randomized to one of the study arms
Eligibility
Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities * Resides in the United States * Endorses feelings of anxiety or stress as a primary issue (desire to reduce anxiety or less stress) * Selects feelings of anxiety/stress, looking to improve their feelings of anxiety/stress, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion criteria
* Pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid physical shipping address * Reports a diagnosis of liver or kidney disease * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Lack of reliable daily access to the internet * Reports taking anticoagulants, any medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs (monoamine oxidase inhibitors) * Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in feelings of anxiety | 4 weeks | Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Minimal clinically important difference (MCID) in anxiety | 4 weeks | Likelihood of experiencing a MCID in anxiety score as assessed by PROMIS Anxiety 8A |
| Change in stress | 4 weeks | Mean difference in stress score as assessed by PROMIS Stress 8A (scale 8-40; where lower scores correspond to less stress) |
| Minimal clinically important difference (MCID) in stress | 4 weeks | Likelihood of experiencing a MCID in stress score as assessed by PROMIS Stress 8A |
| Change in sleep disturbance | 4 weeks | Mean difference in sleep disturbance score as assessed by PROMIS Sleep 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance) |
| Change in cognitive function | 4 weeks | Mean difference in cognitive function score as assessed by PROMIS Cognition Function 4A (scale 4-20; where lower scores correspond to poorer cognitive function) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in mood (emotional distress) | 4 weeks | Mean difference in mood score as assessed by PROMIS Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress) |
| Change in libido | 4 weeks | Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 4-20; where lower scores correspond to less interest in sexual activity) |
Countries
United States
Outcome results
None listed